Literature DB >> 9252798

The perceived effects of smoked cannabis on patients with multiple sclerosis.

P Consroe1, R Musty, J Rein, W Tillery, R Pertwee.   

Abstract

Fifty-three UK and 59 USA people with multiple sclerosis (MS) answered anonymously the first questionnaire on cannabis use and MS. From 97 to 30% of the subjects reported cannabis improved (in descending rank order): spasticity, chronic pain of extremities, acute paroxysmal phenomenon, tremor, emotional dysfunction, anorexia/weight loss, fatigue states, double vision, sexual dysfunction, bowel and bladder dysfunctions, vision dimness, dysfunctions of walking and balance, and memory loss. The MS subjects surveyed have specific therapeutic reasons for smoking cannabis. The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252798     DOI: 10.1159/000112901

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  49 in total

Review 1.  Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.

Authors:  Brian Fiani; Kasra John Sarhadi; Marisol Soula; Atif Zafar; Syed A Quadri
Journal:  Neurol Sci       Date:  2020-06-16       Impact factor: 3.307

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

Authors:  J P Zajicek; H P Sanders; D E Wright; P J Vickery; W M Ingram; S M Reilly; A J Nunn; L J Teare; P J Fox; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

Review 4.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

5.  Diuretic effects of cannabinoid agonists in mice.

Authors:  Girish R Chopda; V Kiran Vemuri; Rishi Sharma; Ganesh A Thakur; Alexandros Makriyannis; Carol A Paronis
Journal:  Eur J Pharmacol       Date:  2013-10-05       Impact factor: 4.432

6.  Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus.

Authors:  Natalia Dmitrieva; Karen J Berkley
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 7.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 8.  Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Authors:  Shokouh Arjmand; Zohreh Vaziri; Mina Behzadi; Hassan Abbassian; Gary J Stephens; Mohammad Shabani
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

Review 10.  Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.

Authors:  Shaheen E Lakhan; Marie Rowland
Journal:  BMC Neurol       Date:  2009-12-04       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.